ArticleJournal of women's health (2002)2026
Treatment Utilization after Uterine Fibroid Diagnosis by Race and Ethnicity.
Article in Journal of women's health (2002), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTreatment utilization after the first fibroid diagnosis has not been well described for patients who are not Black or White. We studied treatment utilization by race and ethnicity in a large, diverse patient cohort. MATERIALS AND
methodsIn the electronic health records of Kaiser Permanente Northern California, we studied 84,206 female patients aged 18-54 from first fibroid diagnosis (January 1, 2009-December 31, 2022) for up to 5 years and ascertained treatments received (levonorgestrel intrauterine device [IUD], hysteroscopic myomectomy, myomectomy, uterine artery embolization, endometrial ablation, hysterectomy). Cox proportional hazards models calculated hazard ratios for receiving any long-term treatment, uterine-preserving treatment, and hysterectomy by race and ethnicity. We assessed effect modification by body mass index (BMI), Neighborhood Deprivation Index (NDI), symptoms, and age. Finally, we calculated the hazard of receiving each treatment as the first treatment.
resultsOverall, 30,838 of 84,206 patients (37%) received 36,115 treatments. The most common treatments were hysterectomy (45% of treatments), levonorgestrel IUD (21%), and myomectomy (15%). Compared with White patients, Black, Asian, and Hispanic patients were significantly less likely to receive any treatment, hysterectomy, or uterine-preserving treatment. This pattern was consistent across age, symptoms, BMI, and NDI. As first treatments, Black patients were more likely than White patients to receive uterine artery embolization, and Black, East Asian, and South Asian patients were more likely to receive myomectomy. White patients were more likely to receive hysteroscopic myomectomy, IUD, endometrial ablation, and hysterectomy as first treatments.
conclusionsDetermining causes of differences in long-term treatment utilization may ensure that access to fibroid care is equitable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.